Pioglitazone attenuates valvular calcification induced by hypercholesterolemia

Area of Science:

• Cardiovascular Research
• Pharmacology
• Molecular Biology

Background:

• Calcific aortic valve stenosis (CAVS) is a complex disease involving multiple signaling pathways.
• Peroxisome proliferator-activated receptor-γ (PPAR-γ) is implicated in the modulation of these pathways.
• PPAR-γ ligands, such as pioglitazone (Pio), represent potential therapeutic targets for CAVS.

Purpose of the Study:

• To investigate the efficacy of pioglitazone (Pio) in inhibiting aortic valve calcification in a mouse model of hypercholesterolemia.
• To determine if Pio has differential effects on the aortic valve compared to the aorta.
• To assess the impact of Pio on aortic valve function and cellular apoptosis.

Main Methods:

• Hypercholesterolemic mice (LDLr-/-/ApoB100/100) were administered a Western diet with or without Pio (20 mg/kg/day) for 6 months.
• Aortic valve and aorta tissues were analyzed for lipid deposition, calcification, and apoptosis markers (active caspase-3, TUNL staining).
• Echocardiography was used to assess aortic valve function. Gene expression analysis was performed in Reversa mice.

Main Results:

• Pio significantly attenuated lipid deposition and calcification in the aortic valve, but not the aorta.
• Pio reduced markers of apoptosis in the aortic valve and improved valve function.
• Gene expression analysis revealed that Pio mitigated the upregulation of procalcific genes in the aortic valve, with no effect on the aorta.

Conclusions:

• Pioglitazone effectively reduces lipid deposition, calcification, and apoptosis in the aortic valves of hypercholesterolemic mice.
• Pio improves aortic valve function and demonstrates preferential effects on the aortic valve over the aorta.
• These findings suggest that PPAR-γ ligands like pioglitazone hold promise for the early intervention and management of calcific aortic valve stenosis.